Get Started With NVIDIA BioNeMo

NVIDIA BioNeMo™ is a generative AI platform for drug discovery that simplifies and accelerates the training of models using your own data and scaling the deployment of models for drug discovery applications. BioNeMo offers the quickest path to both AI model development and deployment, accelerating the journey to AI-powered drug discovery.

Benefits of BioNeMo

State-of-the-Art Biomolecular Models for AI Drug Discovery

Customize and deploy AI models for 3D protein structure prediction, de novo protein and small molecule generation, property predictions, and molecular docking.

Turnkey Solution Through a Web Interface or Cloud APIs

Access pretrained models through cloud APIs or an easy-to-use web interface for interactive inference, visualization, and experimentation.

Seamless and Scalable AI Services

Experience the ultimate flexibility for experimenting and building enterprise-grade generative AI workflows with GUI and API endpoints on scalable, managed infrastructure​.

BioNeMo Packaging and Availability

Training

BioNeMo Training is an end-to-end, optimized training service with state-of-the-art models, data loaders, training workflows, validation in the loop, and enterprise support. It's available as an NGC™ container deployable through the NVIDIA Base Command™ Platform for NVIDIA DGX™ Cloud.

Cloud APIs

BioNeMo cloud APIs allow users to customize and deploy generative AI for drug discovery applications with a user-friendly web interface for rapid evaluation and experimentation while eliminating the need to manage compute infrastructure and maintain complicated software stacks.

Train and Optimize Models on an AI Supercomputer in the Cloud

NVIDIA DGX Cloud is powered by NVIDIA Base Command Platform, a comprehensive AI workflow management software as a service (SaaS) that spans cloud and on-premises resources. Optimize and train models with the multi-node AI training-as-a-service solution.

The BioNeMo Ecosystem

Find More Resources

Access documentation, tutorials, and community support for BioNeMo.